Italia markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
68,84-2,77 (-3,87%)
Alla chiusura: 04:00PM EDT
68,84 0,00 (0,00%)
Dopo ore: 04:56PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments

    Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2022. “We are pleased to report yet a

  • GlobeNewswire

    Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

    CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 9:20 a.m. P.T. / 12:20 p.m. E.T. The fireside chat will be held at the Encore Hotel in Las Vegas, Nev. The presentation will be webcast live under the Events & Presentations section of the inv

  • GlobeNewswire

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 29, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 44 individuals hired by Sarepta in April 2022. The equity awards were approved in accordance with Nasdaq Listing Rul